Table S2 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

MLA

Anthony C. Faber, et al. Table S2 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22470600.

APA

Anthony C. Faber, Hiromichi Ebi, Yasushi Yatabe, Sosipatros Boikos, Aaron N. Hata, Andrew J. Souers, Joel D. Leverson, Hisashi Harada, Jennifer E. Koblinski, Yuko Oya, Brad E. Windle, Colin M. Coon, Krista M. Powell, Bin Hu, Jungoh Ham, Neha U. Patel, Yoshiko Murakami, Timothy L. Lochmann, Sheeba Jacob, … Kyung-A Song. (2023). Table S2 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. https://doi.org/10.1158/1078-0432.22470600

Chicago

Anthony C. Faber, Hiromichi Ebi, Yasushi Yatabe, Sosipatros Boikos, Aaron N. Hata, Andrew J. Souers, Joel D. Leverson, et al. 2023. “Table S2 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target,” March. doi:10.1158/1078-0432.22470600.